SCHEMBL2593348

SCHEMBL2593348

COC(=O)c1ccc(F)c(Cl)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.50
MAPT P10636 4/20 0.48
MAPK1 P28482 1/20 0.43
NPC1 O15118 2/20 0.42
CYP1A2 P05177 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MRGPRX4 Q96LA9 3/20 0.40
MEN1 O00255 1/20 0.40
CASP3 P42574 1/20 0.40
KMT2A Q03164 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
ALDH1A1 P00352 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16101277 0.82 PTPN1 (0.39) PTPN1MAPTSMN1; SMN2
SCHEMBL17144343 0.81 NOTUM (0.46) MAPTMAPK1NPC1CYP1A2RAB9A
SCHEMBL23362438 0.81 MAPT (0.46) PTPN1MAPTMAPK1NPC1CYP1A2
SCHEMBL30405765 0.81 NOTUM (0.46) MAPTMAPK1NPC1CYP1A2RAB9A
SCHEMBL21702391 0.81 PTPN1 (0.40) PTPN1SMN1; SMN2KMT2ALMNA
SCHEMBL16372354 0.80 LCK (0.46) MAPTMAPK1NPC1CYP1A2RAB9A
SCHEMBL31306938 0.80 MAPT (0.45) MAPTMAPK1NPC1CYP1A2RAB9A
SCHEMBL31500498 0.80 SMN1; SMN2 (0.46) MAPTMAPK1NPC1CYP1A2RAB9A
SCHEMBL2255434 0.80 SMN1; SMN2 (0.46) MAPTMAPK1NPC1CYP1A2RAB9A
SCHEMBL1615811 0.80 NPC1 (0.46) MAPTMAPK1NPC1CYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059929-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-19 CN disclosed
CN-122036686-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-15 CN disclosed
CN-122036687-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-15 CN disclosed
CN-122010903-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-12 CN disclosed
US-12606555-B2 Chemical compounds ASTRAZENECA AB (SE) 2026-04-21 US disclosed
EP-4452256-B1 METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS ASTRAZENECA AB (SE) 2025-12-10 EP disclosed
US-20250368615-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2025-12-04 US disclosed
US-20250346573-A1 AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) 2025-11-13 US disclosed
US-12421208-B2 Chemical compounds ASTRAZENECA AB (SE) 2025-09-23 US disclosed
EP-4534533-A1 AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) 2025-04-09 EP disclosed
US-9802918-B2 Pyridineamine compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2017-10-31 US disclosed
US-20170158670-A1 PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2017-06-08 US disclosed
US-9540347-B2 Pyridineamine compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2017-01-10 US disclosed
EP-2566859-B1 PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK CHEMICALS CO LTD (KR) 2016-12-21 EP disclosed
WO-2016196244-A1 PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION (US) 2016-12-08 WO disclosed
US-20160347735-A1 PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2016-12-01 US disclosed
US-9096571-B2 Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same SK CHEMICALS CO., LTD. (KR) 2015-08-04 US disclosed
US-20130210811-A1 PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME SK CHEMICALS CO., LTD. (KR) 2013-08-15 US disclosed
EP-2566859-A2 PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Sk Chemicals Co., Ltd. (KR) 2013-03-13 EP disclosed
WO-2011139107-A2 PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME SK CHEMICALS CO.,LTD. (KR) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368615-A1 CHEMICAL COMPOUNDS CYP11B2, CYP11B1, CYP4B1 PTPN1 2889/4885MAPT 3228/4885MAPK1 2441/4885
US-20160347735-A1 PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 PTPN1 839/4885MAPT 3095/4885MAPK1 104/4885
US-12421208-B2 Chemical compounds CYP11B2, CYP11B1, CYP4B1 PTPN1 2889/4885MAPT 3228/4885MAPK1 2441/4885
US-20130210811-A1 PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME HSD11B1, HSD11B2, G6PC1 PTPN1 525/4885MAPT 3437/4885MAPK1 743/4885
US-12606555-B2 Chemical compounds PARP1, PARP11, PARP12 PTPN1 4653/4885MAPT 4759/4885MAPK1 1293/4885
US-20170158670-A1 PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 PTPN1 839/4885MAPT 3095/4885MAPK1 104/4885
US-20250346573-A1 AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF PARP1, PARP8, PARP11 PTPN1 4409/4885MAPT 622/4885MAPK1 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.